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Background: Early treatment of disseminated intravascular coagulation (DIC) can be associated with improved
patient outcomes. The Japanese Ministry of Health and Welfare (JMHW) and the International Society on
Thrombosis and Haemostasis (ISTH) criteria are the most specific for diagnosis of septic DIC. The revised Japanese
Association for Acute Medicine (JAAM) criteria are able to diagnose sepsis-induced DIC in the early stage.
Recombinant human soluble thrombomodulin (rhTM) has recently been used for treating DIC. Previous studies
have shown a benefit of using rhTM for DIC diagnosed by the JMHW or ISTH criteria, but not the JAAM criteria. The
purpose of this study was to sequentially evaluate coagulation biomarkers and the DIC score after giving rhTM
treatment to patients with sepsis-induced DIC diagnosed according to the JAAM criteria.
Methods: We performed a retrospective cohort study. Critically ill patients were included if diagnosed with sepsis-
induced DIC according to the JAAM criteria. They were either treated without rhTM (control group) or with rhTM
(treatment group). The primary outcome was the DIC score on day 7. The secondary outcome was 28-day mortality
from the start of DIC treatment. Changes in the results of coagulation tests were assessed over time from the start
of treatment to day 7.
Results: Twelve and 23 patients were assigned to the treatment and control groups, respectively. The DIC score on
day 7 was significantly higher in the treatment group (3.3 ± 1.4) than in the control group (4.9 ± 1.8, p < 0.05).
Estimated survival showed lower in treatment group than control group. There was significant difference between
the control group and the treatment group (p < 0.05). The D-dimer level on day 7 was significantly lower in the
treatment group (7.5 ± 4.1 μg/mL) than in the control group (30.9 ± 33.6 μg/mL, p < 0.05). Life-threatening
bleeding did not occur. Our results indicated that rhTM improved sepsis-induced DIC and mortality.
Conclusions: Recombinant human soluble thrombomodulin may improve sepsis-induced DIC diagnosed according
to the JAAM criteria without an increased bleeding risk.
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Disseminated intravascular coagulation (DIC) is associated
with high mortality in patients with severe sepsis. Ex-
cessive coagulation activation, inhibition of fibrinolysis,
and consumption of coagulation inhibitors lead to a
hypercoagulable state, resulting in fibrin deposition in
microvessels and inflammatory reactions. Although the
effectiveness of anticoagulant therapy in septic patients
is still controversial worldwide, some studies have
suggested that rapid diagnosis and early treatment of
DIC improve outcomes for these patients. In particular,
therapeutic intervention directly against coagulation
and inflammation in DIC associated with severe sepsis
is effective [1,2], and it is generally accepted that early,
aggressive treatment of the underlying disease is
important.
Recently, the International Society on Thrombosis
and Haemostasis (ISTH) criteria were proposed by the
subcommittee of the ISTH. The revised Japanese
Association for Acute Medicine (JAAM) criteria were
proposed by the JAAM, and the Japanese Ministry of
Health and Welfare (JMHW) criteria were proposed by
the JMHW. These criteria have been used for clinical
diagnosis of DIC [3-5]. The JAAM criteria have accept-
able validity for diagnosis of DIC in the early phase of
disease, and the scoring system can diagnose DIC with a
higher sensitivity than can the criteria of the ISTH for
overt DIC [6], thus enabling patients to receive early
treatment.
The novel biological agent recombinant human soluble
thrombomodulin (rhTM) was recently approved and has
been used clinically for DIC treatment in Japan. The
clinical effects of rhTM on DIC were previously
examined in patients diagnosed according to the JMHW
criteria in a multicenter randomized clinical trial
conducted in Japan [7]. This study revealed significantly
better resolution of DIC in the rhTM treatment group
than in the heparin treatment group. Only non-significant
trends in favor of rhTM compared with heparin were
observed for mortality in patients with sepsis-induced
DIC [7]. Yamakawa et al. showed that administration of
rhTM reduced 28-day mortality in patients with severe
sepsis [8].
However, the clinical effects of rhTM on patients
diagnosed in the early stage of sepsis-induced DIC
according to the JAAM criteria have not been assessed.
Because the JAAM criteria show higher sensitivity for
DIC diagnosis than do the ISTH criteria, and because
early treatment of DIC may be associated with improved
outcomes [1], rhTM treatment in patients diagnosed
with sepsis-induced DIC according to the JAAM criteria
may enhance clinical outcomes. Therefore, the purpose
of this study was to sequentially evaluate coagulation
biomarkers and the DIC score in rhTM treatment ofpatients with sepsis-induced DIC diagnosed according to
the JAAM criteria.
Methods
Patients and study design
A retrospective analysis of all patients admitted to the
intensive care unit (ICU) of Aichi Medical University
Hospital between May 2008 and March 2011 was
performed. Although the criteria for ICU admission
were not standardized, all patients included in this study
were diagnosed with sepsis-induced DIC according to
the JAAM criteria. Administration of rhTM started
within 48 h from the initiation of DIC treatment. Treat-
ment with rhTM (0.06 or 0.02 mg/kg/day; patients who
required renal replacement therapy for acute kidney in-
jury [AKI] were drip-infused for 30 min once daily) was
continued for 7 days. There was no difference in treat-
ment strategy among all patients, equipment used, or
number of physicians and nurses who took care of the
patients during the study period. All patients were prin-
cipally treated according to the strategy of the Surviving
Sepsis Campaign Guidelines [9]. Any patients who
lacked the required laboratory data were excluded, and
other exclusion criteria were as follows: acute pancrea-
titis, burns, treatment with danaparoid sodium, fatal or
life-threatening bleeding (defined as intracranial or pul-
monary bleeding) at the start of treatment for DIC, and
age of ≤15 years. A patient flow diagram is shown in
Figure 1.
The protocol was reviewed and approved by a local in-
stitutional review board. Informed consent was not
required because blood samples were taken as part of
the routine patient care for clinical laboratory testing,
but the highest standard of privacy policy was applied.
Data collection
Relevant clinical background, medication history, and
laboratory data of all patients were collected at appro-
priate times during the treatment for sepsis. The
variables compared between the two groups were age,
sex, Acute Physiologic and Chronic Health Evaluation
II (APACHE II) score, Sequential Organ Failure Assess-
ment (SOFA) score, number of dysfunctional organs,
shock (hypotension not reversed with fluid resuscita-
tion), presence of AKI as defined by the Acute Kidney
Injury Network [10], acute respiratory distress syn-
drome (ARDS), DIC score (calculated with the JAAM
criteria) at the start of DIC treatment, maximum DIC
score during DIC treatment, number of patients who
fulfilled the ISTH criteria, platelet count, prothrombin
time (PT) ratio, D-dimer level, antithrombin III (AT
III) activity, renal replacement therapy, mechanical ven-
tilation, use of vasopressors, administration of AT III,
low-dose steroids, platelet concentrate, fresh frozen









Control group Treatment group
Use of rhTM after 48hr (n=1)
Figure 1 Patient flow diagram. DIC, disseminated intravascular coagulation; rhTM, recombinant human soluble thrombomodulin.
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site of infection. Patients were followed until day 28
after the start of DIC treatment.
Evaluation of clinical response
The DIC score and DIC resolution rate (rate of recovery
from DIC) were assessed 7 days after the start of DIC
treatment (or withdrawal) based on the JAAM criteria as
the primary efficacy endpoint. Secondary endpoints were
as follows: the 28-day mortality from the start of DIC
treatment; severity of the patients’ conditions as
calculated by the SOFA score from the start of treatment
to day 28; and changes over time in the results of coagu-
lation tests, such as the platelet count, D-dimer level, PT
ratio, fibrinogen level, and AT III activity, were also
assessed from the start of treatment to day 7. In
addition, the presence of serious adverse events related
to bleeding (defined as intracranial hemorrhage, gastro-
intestinal or respiratory tract bleeding that was uncon-
trollable by conservative treatments, and bleeding at a
critical location, such as retinal hemorrhage, major
hemarthrosis, spinal hemorrhage or any life-threatening
bleeding) that led to discontinuation of the administrated
study drug and abnormal changes in clinical laboratory
test results related to the diagnosis of DIC were
investigated.
Statistical analysis
Data are expressed as group means ± standard deviation
or percentages, as appropriate. Continuous variables
were compared between groups using the Student’s t-test.
Noncontinuous variables were compared between groups
using the Mann–Whitney test. Categorical variables wereanalyzed using the χ2 test or Fisher’s exact test, as appro-
priate. Univariate analysis of the time to DIC resolution
and the mortality rate were compared using Wilcoxon’s
test. In addition, stepwise multivariate Cox regression ana-
lysis was used to assess the covariates that were associated
with time to mortality. Adjusted curves of time to mortal-
ity by associated covariates were estimated. Comparisons
of DIC scores, SOFA scores, D-dimer level, platelet count,
PT ratio, fibrinogen, and AT III activity between groups
over time were analyzed by repeated measures analysis of
variance (ANOVA) adjusted for the baseline values as a
covariate, and by post hoc Bonferroni test. The last-
observation-carried-forward method for missing data was
used for the analysis. Missing samples occurred because
some samples were not drawn. A p value of <0.05 was
considered statistically significant. Statistical analyses,
except for ANOVA and the post-hoc Bonferroni test,
were performed using JMP for Windows version 5.0.1
software (SAS Institute, Inc, U.S.). ANOVAs and post
hoc Bonferroni tests were performed using Microsoft
Excel 2010 (Microsoft Corporation, U.S.).
Results
Baseline characteristics
During the study period, although 49 patients were
diagnosed with DIC, only 35 patients met the requirements
of our study. Fourteen patients were excluded (acute pan-
creatitis, 2; burns, 12). Twelve patients were treated with
rhTM for DIC (treatment group) and 23 patients were
treated without rhTM (control group). All patients were
regarded as having been infected with pathogens. Baseline
characteristics and therapeutic interventions of the study
population are shown in Table 1. Twenty-four patients
Table 1 Characteristics and diagnostic data of the patients
Control group (n = 23) Treatment group (n = 12) P value
Age 70.9 ± 13.7 60.6 ± 19.2 0.117
Male (%) 16 (69.6) 8 (66.7) 0.919
APACHE II score 29.2 ± 8.5 26.6 ± 8.6 0.395
SOFA score (day 1) 11.7 ± 3.4 10.5 ± 2.5 0.418
Number of dysfunctional organs 3.7 ± 1.0 3.5 ± 0.7 0.450
Shock 11 (47.8) 5 (41.7) 0.728
AKI 13 (56.5) 5 (41.7) 0.404
ARDS 15 (65.2) 8 (66.7) 0.618
DIC score (day 1) 5.8 ± 1.2 5.7 ± 1.4 0.881
DIC score (max) 6.7 ± 1.02 6.33 ± 1.33 0.703
ISTH criteria (%) 9 (39.1) 5 (41.7) 0.884
Platelet count (103/μl) 94.3 ± 49.6 65.6 ± 48.3 0.130
Prothrombin time ratio 1.52 ± 0.39 1.48 ± 0.41 0.759
D-dimer (mg/ml) 26.9 ± 35.3 55.1 ± 133.1 0.486
AT III activity (%) 51.3 ± 19.0 61.3 ± 20.5 0.264
Renal replacement therapy (%) 13 (56.5) 8 (66.7) 0.559
Mechanical ventilation (%) 23 (100) 12 (100) -
Use of vasopressor (%) † 21 (91.3) 10 (83.3) 0.482
Use of low-dose steroid (%) 1 (4.35) 1 (8.33) 0.630
Use of AT III (%) 16 (69.6) 5 (41.7) 0.111
Use of Platelet concentrate (%) 10 (43.5) 8 (66.7) 0.189
Use of fresh frozen plasma (%) 15 (65.2) 8 (66.7) 0.932
Positive blood culture (%) 7 (31.8)* 7 (58.3) 0.134
Period for rhTM administration (day) - 5.8 ± 1.3 -
Sites of infection
Lung (%) 9 (39.1) 4 (33.3) 0.735
Abdomen (%) 7 (30.4) 4 (33.3) 0.735
Urinary tract (%) 2 (8.7) 2 (16.7) 0.364
Other (%) 5 (21.8) 3 (25.0) 0.203
No significant differences were observed between the control and treatment groups.
*Blood culture was not performed in one patient.
†Vasopressors not only were used for sepsis but also before the onset of sepsis-induced DIC and were used to maintain circulation for surgery.
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7 days (5.83 ± 1.26 days). Baseline characteristics, including
severity of underlying disease, DIC scores, and treatment
excluding rhTM administration showed no significant
differences between the control and treatment groups. The
ratio of patients diagnosed with DIC according to the
ISTH criteria was 39.1% (9 of 23) for the control group
and 41.7% (5 of 12) for the treatment group.
Primary endpoint
On day 7, the DIC score was significantly lower in the
treatment group (3.3 ± 1.4) than in the control group
(4.9 ± 1.8, p < 0.05, Figure 2). The DIC resolution rate
was significantly higher in the treatment group (58.3%)
than in the control group on day 7 (26.1% p = 0.079,Figure 3). While three patients in the control group died
before 7 days, no patient in the treatment group died
before 7 days.
Secondary endpoints
The 28-day mortality rate in the control group was
33.3% (8 of 23 patients) compared with 8.3% (1 of
12 patients) in the treatment group (p = 0.075 by
Wilcoxon’s test). We performed Cox regression analysis
to adjust for the baseline variables of patients. We
assessed a total of 11 possible confounders related to
outcome: age, sex, APACHE II score, SOFA score, ful-
filled ISTH criteria at the start of DIC treatment, AKI,
ARDS, use of AT III, platelet concentrate, fresh frozen



















Figure 2 Serial changes in the DIC score in the two groups. Data are expressed as group means ± standard deviation. The DIC score
decreased over time in the treatment group (p < 0.05). The interaction between treatment and time was statistically significant (p < 0.01). The
degree of decrease in the DIC score was significantly greater in the treatment group than in the control group. *p < 0.05 compared with the
control group, †p < 0.05 compared with baseline.
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tion of rhTM. After adjusting for AKI and rhTM admin-
istration was identified as an independent significant
predictor of the probability of 28-day mortality (adjusted
hazard ratio, 0.089 to 0.904; P = 0.026) (Table 2). The
survival curves of the prediction model calculated by
Cox regression analysis are shown in Figure 4. Estimated
survival showed higher in treatment group than control
group. There was significant difference between the con-
trol and the treatment groups (p < 0.05). The SOFA























Figure 3 DIC resolution curves in Wilcoxon models. The solid line repre
patients in the control group. The DIC resolution rate increased over time i
degree in the treatment group than in the control group (p = 0.079).groups (Figure 5). In the coagulation tests, D-dimer level
was significantly lower on day 7 (7.5 ± 4.1 μg/ml in the
treatment group vs 30.9 ± 33.6 μg/ml in the control
group; p < 0.01), while the platelet count, PT ratio, and
fibrinogen levels were not significantly different at day 7
between the groups (Figure 6). AT III was used when
the physician considered that it was required. AT III was
administrated at a concentration of1500 IU per day for
less than 3 days. AT III was not administrated after day
4. AT III activity was not significantly different at day 7
between the two groups, and showed a significantControl group
Treatment group
4 5 6 7 (days)
sents patients in the treatment group, and the dotted line represents
n both groups. The DIC resolution rate was improved to a greater
Table 2 Independent variables in final multiple regression models by Cox regression analysis
Variables Coefficient Hazard ratio 95% CI P value
rhTM administration −0.958 0.384 0.088 to 0.904 0.026
AKI 0.840 2.316 1.132 to 6.016 0.020
rhTM, recombinant human soluble thrombomodulin; AKI, acute kidney injury; CI, confidence interval.
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in the control group (Figure 7).
Until 28 days after the start of DIC treatment, one ser-
ious adverse event related to bleeding occurred in the
control group (4.3%) and no serious adverse events oc-
curred in the treatment group (0%) within 28 days. No
clear correlation was shown between these adverse
events and the treatment used. There was no significant
difference in the incidence of these adverse events be-
tween the two groups (p = 1.00).
Discussion
The results of this study provide evidence that rhTM
may have a beneficial effect on coagulation in patients
with sepsis-induced DIC diagnosed according to the
JAAM criteria. We showed a significant decrease in the
DIC score in the treatment group compared with that in
the control group. The DIC resolution rate was higher
and the mortality rate was lower in the treatment group
than in the control group. Bleeding showed no signifi-
cant difference between the two groups.
Early treatment of DIC may be associated with
improved outcomes [1]. In our study, the number of
patients who fulfilled the ISTH criteria did not show a
significant difference between the two groups. In the























Figure 4 Adjusted estimated survival curves by the covariate of AKI i
treatment group, and the dotted line represents patients in the control gro
rate of survival (P = 0.026 by Cox regression analysis). AKI, acute kidney injuthe early phase of DIC compared with the diagnosis
according to the ISTH criteria. Mortality has been
shown to be correlated with the maximum DIC score
[5]. In our study, the maximum DIC score, APACHE II
score, SOFA score, AKI, and ARDS showed no signifi-
cant differences between the control and treatment
groups at baseline. Therefore, it was considered reason-
able to compare the two groups.
Several DIC markers were assessed. It was difficult to
assess the platelet count and AT III activity because they
varied widely among the patients, and platelet concen-
trate was used for approximately half of the patients in
the two groups. However, we consider that the contribu-
tion of rhTM administration to the increases in platelet
counts was not large because there was no significant
difference in improvement in the platelet counts be-
tween the two groups. In addition, we consider that the
contribution of platelet concentrate to the DIC score
was not large because the platelet count was <80,000/μl
after the use of platelet concentrate at approximately
day 7. Although AT III activity decreased from days 3 to
7 in the control group, it did not decrease with rhTM
administration. This suggests that rhTM improves
sepsis-induced DIC by not decreasing AT III activity.
Recombinant human soluble thrombomodulin decreases





n Cox regression models. The solid line represents patients in the
up. Treatment with rhTM was associated with a significantly higher
ry; rhTM, recombinant human soluble thrombomodulin.



















Figure 5 Serial changes in the SOFA score in the two groups. Data are expressed as group means ± standard deviation. Although the SOFA
score was not significantly different between the two groups (p = 0.493), the interaction between treatment and time was statistically significant
(p < 0.001). †p < 0.05 compared with baseline.
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not decrease in the treatment group.
The sensitivity of a low fibrinogen level for the diagno-
sis of DIC according to ISTH criteria was 28% and
hypofibrinogenemia has been detected in severe cases of
DIC only [11]. Although rhTM improves fibrinogen
levels in animal studies [12,13], fibrinogen levels were
normal in all patients in the present study. Therefore,
fibrinogen levels showed no significant differences be-
tween the control and treatment groups.
D-dimer levels were significantly decreased in the








































Figure 6 Serial changes in coagulation tests in the two groups. Data a
interaction between treatment and time in D-dimer (p = 0.289), Prothromb
compared with the control group. †p < 0.05 compared with baseline.day 7. In a phase III trial of rhTM for patients with DIC,
Saito et al. showed that the rate of change in D-dimer
levels in the rhTM group was significantly greater than
that in the heparin group, suggesting that rhTM is super-
ior to heparin in the attenuation of the hypercoagulable
state [7]. Yamakawa et al. showed that rhTM decreased
fibrin degradation products in patients with DIC who
fulfilled the ISTH criteria [8]. Therefore, it is thought
that rhTM affects the treatment of not only overt DIC,
but also the early phase of DIC as diagnosed by the JAAM
criteria. Recombinant human soluble thrombomodulin







































re expressed as group means ± standard deviation. There were no
in time ratio (p = 0.457) and Fibrinogen level (p = 0.528). *p < 0.01



















Figure 7 Serial changes in AT III activity in the two groups. Data are expressed as group means ± standard deviation. There were no
interaction between treatment and time (p = 0.618). Changes over time of AT III activity were not significantly different in the treatment group,
and they showed a significant decrease compared with the maximum level and day 5 and 7 in the control group. *p < 0.01 compared with the
control group, †p < 0.05 compared with baseline, ‡ p < 0.05 compared with day 3.
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prothrombinase compared with heparin, thus producing
an anti-thrombin effect [12,14]. Although it is considered
that regulation of coagulation and activation of fibrinolysis
are mechanisms of decreasing D-dimer levels, rhTM does
not affect the fibrinolytic system [15]. Therefore, rhTM
suppresses the hypercoagulative state in patients with
sepsis-induced DIC. As a result, the D-dimer level was
decreased and the PT ratio did not decrease in the treat-
ment group in our study.
Although the accuracy of the mortality rate was ques-
tionable because of the small sample size, Cox regression
analysis indicated that 28-day mortality of the patients
treated with rhTM was significantly improved compared
with that in the patients treated without rhTM.
In our study, the SOFA score did not show a signifi-
cant difference on days 7 or 28. Although Yamakawa
et al. [8] showed that rhTM did not decrease the SOFA
score on day 7 compared with the control group, organ
damage was improved on days 21 and 28 by rhTM ad-
ministration, and the 28-day mortality was significantly
improved. They investigated patients with DIC diagnosed
according to the ISTH criteria. However, in the present
study, we investigated patients with DIC diagnosed
according to the JAAM criteria. SOFA score might have
been nonsignificant because of the small sample size.
Several animal studies have demonstrated a reduction
in mortality with the administration of rhTM in severe
sepsis models. Iba et al. [13] showed that changes in co-
agulation abnormalities were reduced and that mortalitywas decreased by the concomitant administration of
rhTM and antithrombin in rats with lipopolysaccharide
infusion-induced sepsis, which are similar results to our
study. Therefore, decreased mortality is expected, not
only in patients with overt DIC, but also in patients in
the early phase of DIC as diagnosed by the JAAM cri-
teria. D-dimer levels are decreased by recombinant
APC [16]; however, APC does not reduce the 28-day mor-
tality [17]. Recombinant human soluble thrombomodulin
treatment might have the same effect. Further evaluation
of the effects of rhTM is necessary.
Bleeding is the most significant adverse event associated
with the administration of rhTM, as it is with recombinant
human APC [18]. Sadaka et al. reported that life-
threatening bleeding was higher in the APC group than in
the placebo group [19]. In the present study, the PT ratio
and bleeding were not significant between the two groups.
Moreover, life-threatening bleeding did not occur. Recom-
binant human soluble thrombomodulin was considered
not to increase the risk of bleeding based on our study
results. Clinical doses of APC and rhTM do not affect the
clotting time [12,20]. Therefore, PT is not a predictive fac-
tor of bleeding by rhTM. This is supported by the fact that
there was no significant difference in bleeding between
the two groups; the anticoagulative effect of rhTM
depends on the amount of thrombin available. Accord-
ingly, after controlling thrombin generation by rhTM
administration, rhTM does not work in excess and gen-
eration of further APC decreases. Recombinant human
soluble thrombomodulin has been shown to have a
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profile with less bleeding than heparin in animals and
in in vitro experiments [12].
We acknowledge several limitations of our observa-
tional study design. This study was not a randomized
controlled trial, and we compared two groups retro-
spectively. A small number of patients was included in
this study. Finally, this study was carried out in a single
institution. Further multicenter, prospective, randomized
trials are necessary to fully evaluate the effects of rhTM.
Conclusions
Recombinant human soluble thrombomodulin adminis-
tration may improve sepsis-induced DIC diagnosed
according to the JAAM criteria without an increased
bleeding risk. Further clinical investigations are neces-
sary to fully evaluate the effect of rhTM.
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